PE20030257A1 - Analogos de 8-aza-11-desoxi-prostaglandina como agonistas del receptor ep4 - Google Patents
Analogos de 8-aza-11-desoxi-prostaglandina como agonistas del receptor ep4Info
- Publication number
- PE20030257A1 PE20030257A1 PE2002000619A PE2002000619A PE20030257A1 PE 20030257 A1 PE20030257 A1 PE 20030257A1 PE 2002000619 A PE2002000619 A PE 2002000619A PE 2002000619 A PE2002000619 A PE 2002000619A PE 20030257 A1 PE20030257 A1 PE 20030257A1
- Authority
- PE
- Peru
- Prior art keywords
- sup
- sub
- aryl
- heteroaryl
- receptor agonists
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/24—Oxygen or sulfur atoms
- C07D207/26—2-Pyrrolidones
- C07D207/263—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms
- C07D207/27—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms with substituted hydrocarbon radicals directly attached to the ring nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/06—Antiabortive agents; Labour repressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/24—Oxygen or sulfur atoms
- C07D207/26—2-Pyrrolidones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Physical Education & Sports Medicine (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Endocrinology (AREA)
- Pulmonology (AREA)
- Ophthalmology & Optometry (AREA)
- Reproductive Health (AREA)
- Diabetes (AREA)
- Pregnancy & Childbirth (AREA)
- Gynecology & Obstetrics (AREA)
- Hematology (AREA)
- Transplantation (AREA)
- Gastroenterology & Hepatology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyrrole Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
SE REFIERE A ANALOGOS 8-AZA-11-DESOXI DE PROSTAGLANDINAS DE FORMULA I DONDE A ES (CH2)2, HC=CH; B ES ARILO, HETEROARILO O ESTA AUSENTE; Z ES COOR', CONR'R", CONSO2R', PR'O(OR'), PO(OR')2, TETRAZOL-5-IL; R' Y R" SON H, ALQUILO C1-C6; m ES 1-6; R1 ES ALQUILO, ALQUENILO, ALQUINILO, CICLOALQUILALQUILO, HETEROCICLILALQUILO, ARILO, ARILALQUILO, ENTRE OTROS; CUANDO B ES ARILO, HETEROARILO; R3, R4, R5, R6 NO SON A LA VEZ H; R1 ES HETEROCICLILALQUILO, ARILO, HETEROARILO; CUANDO B ESTA AUSENTE, R3, R4, R5, R6 SON TODOS H; R2 ES H, ALQUILO C1-C6, ALQUENILO C1-C6, ALQUINILO C1-C6; R3, R4, R5, R6 SON H, ALQUILO C1-C6; O R3 Y R4, R5 Y R6, R3 Y R5 JUNTO AL ATOMO QUE ESTAN UNIDOS FORMAN ANILLO ALQUILO C3-C7. SON COMPUESTOS PREFERIDOS ACIDO 7-{(R)-2-[(TRANS)-3-(4'-CLORO-2'-METILBIFENIL-3-IL)-3-HIDROXIPROPENIL]-5-OXO-PIRROLIDIN-1-IL}-HEPTANOICO; ACIDO 7-{(R)-2-[3-(4-CLORO-2'-METIL-BIFENIL-3-IL)-3-HIDROXI-PROPIL]-5-OXO-PIRROLIDIN-1-IL}-HEPTANOICO; ENTRE OTROS. TAMBIEN SE REFIERE A UN PROCEDIMIENTO PARA LA PREPARACION. LOS COMPUESTOS SON AGONISTAS DE EP4 Y PUEDEN SER UTILES PARA EL TRATAMIENTO DE TRASTORNOS OSEOS
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US30572701P | 2001-07-16 | 2001-07-16 | |
US37134802P | 2002-04-10 | 2002-04-10 |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20030257A1 true PE20030257A1 (es) | 2003-03-21 |
Family
ID=26974750
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2002000619A PE20030257A1 (es) | 2001-07-16 | 2002-07-11 | Analogos de 8-aza-11-desoxi-prostaglandina como agonistas del receptor ep4 |
Country Status (17)
Country | Link |
---|---|
US (1) | US6900336B2 (es) |
EP (1) | EP1409455B1 (es) |
JP (1) | JP2004521954A (es) |
KR (1) | KR20040015364A (es) |
AT (1) | ATE315022T1 (es) |
AU (1) | AU2002328855B2 (es) |
BR (1) | BR0211201A (es) |
CA (1) | CA2451392A1 (es) |
DE (1) | DE60208568T2 (es) |
ES (1) | ES2254726T3 (es) |
MX (1) | MXPA04000456A (es) |
PA (1) | PA8550201A1 (es) |
PE (1) | PE20030257A1 (es) |
PL (1) | PL368046A1 (es) |
RU (1) | RU2288913C2 (es) |
UY (1) | UY27384A1 (es) |
WO (1) | WO2003008377A1 (es) |
Families Citing this family (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE455758T1 (de) * | 2001-12-20 | 2010-02-15 | Merck Serono Sa | Pyrrolidin-derivatie als prostaglandin- modulatoren |
WO2003074483A1 (fr) | 2002-03-05 | 2003-09-12 | Ono Pharmaceutical Co., Ltd. | Composes derives de 8 azaprostaglandine et medicaments contenant ceux-ci comme principe actif |
EP1490055A1 (en) * | 2002-03-18 | 2004-12-29 | Pfizer Products Inc. | Use of selective ep4 receptor agonists for the treatment of liver failure, loss of patency of the ductus arteriosus, glaucoma or ocular hypertension |
US6573294B1 (en) | 2002-05-14 | 2003-06-03 | Allergan, Inc. | 8-azaprostaglandin analogs as agents for lowering intraocular pressure |
WO2003103604A2 (en) * | 2002-06-01 | 2003-12-18 | Applied Research Systems Ars Holding N.V | Gamma lactams as prostaglandin agonists and use thereof |
JP2006505572A (ja) * | 2002-10-25 | 2006-02-16 | メルク フロスト カナダ アンド カンパニー | Ep4受容体アゴニストとしての2−ピロリドン |
CA2513652A1 (en) * | 2003-03-03 | 2004-09-16 | Applied Research Systems Ars Holding N.V. | G-lactam derivatives as prostaglandin agonists |
US6734206B1 (en) * | 2003-06-02 | 2004-05-11 | Allergan, Inc. | 3-oxa-8-azaprostaglandin analogs as agents for lowering intraocular pressure |
US7179820B2 (en) * | 2003-06-06 | 2007-02-20 | Allergan, Inc. | Piperidinyl prostaglandin E analogs |
CA2528179C (en) * | 2003-06-06 | 2013-10-22 | Allergan, Inc. | Piperidinyl prostaglandin e analogs |
WO2005061492A1 (ja) * | 2003-12-22 | 2005-07-07 | Ono Pharmaceutical Co., Ltd. | 含窒素複素環化合物およびそれらを有効成分とする薬剤 |
JP4893999B2 (ja) | 2004-10-22 | 2012-03-07 | 小野薬品工業株式会社 | 吸入用医薬組成物 |
JP2008518013A (ja) * | 2004-10-26 | 2008-05-29 | アラーガン、インコーポレイテッド | プロスタグランジンep4アゴニストによる処置方法およびデリバリー方法 |
AU2005304764B2 (en) | 2004-11-08 | 2012-07-12 | Allergan, Inc. | Substituted pyrrolidone compounds as EP4 agonists |
AU2006223514A1 (en) * | 2005-03-10 | 2006-09-21 | Allergan, Inc. | Substituted gamma lactams as therapeutic agents |
AU2012211448B2 (en) * | 2005-03-10 | 2016-01-07 | Allergan, Inc. | Substituted gamma lactams as therapeutic agents |
ATE515263T1 (de) * | 2005-05-06 | 2011-07-15 | Allergan Inc | Substituierte beta-lactame und deren verwendung in der medizin |
US7893107B2 (en) | 2005-11-30 | 2011-02-22 | Allergan, Inc. | Therapeutic methods using prostaglandin EP4 agonist components |
US7592364B2 (en) * | 2006-02-28 | 2009-09-22 | Allergan, Inc. | Substituted gamma lactams as therapeutic agents |
US20070232660A1 (en) * | 2006-04-04 | 2007-10-04 | Allergan, Inc. | Therapeutic and delivery methods of prostaglandin ep4 agonists |
ATE502914T1 (de) * | 2006-08-09 | 2011-04-15 | Allergan Inc | Therapeutische amide und entsprechende verbindungen |
CN101595106B (zh) * | 2007-01-31 | 2014-05-07 | 阿勒根公司 | 作为治疗药物的取代的γ内酰胺 |
JP5566696B2 (ja) * | 2007-02-15 | 2014-08-06 | アラーガン インコーポレイテッド | 緑内障または上昇眼内圧の治療用ガンマ‐ラクタム類 |
CN101686985A (zh) | 2007-05-08 | 2010-03-31 | 国立大学法人浜松医科大学 | 含有ep4激动剂的细胞毒性t细胞的活化剂 |
CN101868455B (zh) * | 2007-10-23 | 2013-11-13 | 阿勒根公司 | 治疗性的取代的内酰胺 |
US8063033B2 (en) * | 2008-01-18 | 2011-11-22 | Allergan, Inc. | Therapeutic beta-lactams |
US8202855B2 (en) | 2008-03-04 | 2012-06-19 | Allergan, Inc | Substituted beta-lactams |
MX2010011636A (es) * | 2008-04-24 | 2010-11-25 | Allergan Inc | Gamma lactamas sustituidas como agentes terapeuticos. |
WO2010006059A1 (en) * | 2008-07-08 | 2010-01-14 | Abbott Laboratories | Prostaglandin e2 binding proteins and uses thereof |
US7985765B2 (en) * | 2008-08-20 | 2011-07-26 | Allergan, Inc. | Therapeutic substituted pyrroles |
BRPI0918134B1 (pt) * | 2008-09-10 | 2019-02-12 | Kaken Pharmaceutical Co., Ltd | Derivado de prostaglandina i2 |
US8697057B2 (en) * | 2010-08-19 | 2014-04-15 | Allergan, Inc. | Compositions and soft tissue replacement methods |
RU2627842C2 (ru) * | 2011-08-02 | 2017-08-14 | Оно Фармасьютикал Ко., Лтд. | Средство для улучшения диастолической функции левого желудочка |
WO2014015247A1 (en) | 2012-07-19 | 2014-01-23 | Cayman Chemical Company, Inc. | Difluorolactam compounds as ep4 receptor-selective agonists for use in the treatment of ep4-mediated disease and conditions |
US9676712B2 (en) | 2013-03-15 | 2017-06-13 | Cayman Chemical Company, Inc. | Lactam compounds as EP4 receptor-selective agonists for use in the treatment of EP4-mediated diseases and conditions |
AU2014229065B2 (en) | 2013-03-15 | 2017-03-09 | Cayman Chemical Company, Inc. | Methods of synthesizing a difluorolactam analog |
EP3235817B1 (en) | 2013-03-15 | 2018-12-12 | Cayman Chemical Company, Incorporated | Lactam compounds as ep4 receptor-selective agonists for use in the treatment of ep4-mediated diseases and conditions |
AU2014290512A1 (en) | 2013-07-19 | 2015-11-12 | Cayman Chemical Company, Inc. | Methods, systems, and compositions for promoting bone growth |
GB201914585D0 (en) * | 2019-10-09 | 2019-11-20 | Heptares Therapeutics Ltd | Prostaglandin ep4 receptor antagonist compounds |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3975399A (en) | 1974-08-06 | 1976-08-17 | E. I. Du Pont De Nemours And Company | 1,5-Disubstituted-2-pyrrolidinones, -3-pyrrolin-2-ones, and -4-pyrrolin-2-ones |
US4113873A (en) | 1975-04-26 | 1978-09-12 | Tanabe Seiyaku Co. Ltd. | 8-azaprostanoic acid derivatives |
NL7604330A (nl) | 1975-04-28 | 1976-11-01 | Syntex Inc | Werkwijze voor de bereiding van 8-azaprostaan- zuurderivaten. |
DE2556326A1 (de) | 1975-12-13 | 1977-06-23 | Hoechst Ag | Neue pyrrolidone und verfahren zu ihrer herstellung |
DE2528664A1 (de) | 1975-06-27 | 1977-01-13 | Hoechst Ag | Pyrrolidone und verfahren zu ihrer herstellung |
IL49325A (en) | 1976-03-31 | 1979-11-30 | Labaz | 8-aza-11-deoxy-pge1 derivatives,their preparation and pharmaceutical compositions containing them |
DE2619638A1 (de) * | 1976-05-04 | 1977-11-17 | Hoechst Ag | Pyrrolidone und verfahren zu ihrer herstellung |
US4177346A (en) | 1976-08-06 | 1979-12-04 | Pfizer Inc. | 1,5-Disubstituted-2-pyrrolidones |
US4320136A (en) | 1980-08-11 | 1982-03-16 | E. I. Du Pont De Nemours And Company | 8-Aza-16,16-difluoroprostanoids |
EP1121133A1 (en) | 1998-10-15 | 2001-08-08 | Merck & Co., Inc. | Methods for stimulating bone formation |
AU1444200A (en) | 1998-10-15 | 2000-05-01 | Merck & Co., Inc. | Methods for inhibiting bone resorption |
WO2001046140A1 (en) | 1999-12-22 | 2001-06-28 | Pfizer Products Inc. | Ep4 receptor selective agonists in the treatment of osteoporosis |
WO2002024647A1 (fr) | 2000-09-21 | 2002-03-28 | Ono Pharmaceutical Co., Ltd. | Agonistes du recepteur de l'ep4 comprenant comme principe actif des derives de la 8-azaprostaglandine |
SK5562003A3 (en) * | 2000-11-27 | 2004-08-03 | Pfizer Prod Inc | EP4 receptor selective agonists in the treatment of osteoporosis |
-
2002
- 2002-07-08 KR KR10-2004-7000623A patent/KR20040015364A/ko active IP Right Grant
- 2002-07-08 JP JP2003513937A patent/JP2004521954A/ja active Pending
- 2002-07-08 BR BR0211201-9A patent/BR0211201A/pt not_active IP Right Cessation
- 2002-07-08 MX MXPA04000456A patent/MXPA04000456A/es active IP Right Grant
- 2002-07-08 EP EP02764647A patent/EP1409455B1/en not_active Expired - Lifetime
- 2002-07-08 WO PCT/EP2002/007574 patent/WO2003008377A1/en active IP Right Grant
- 2002-07-08 PL PL02368046A patent/PL368046A1/xx not_active Application Discontinuation
- 2002-07-08 DE DE60208568T patent/DE60208568T2/de not_active Expired - Fee Related
- 2002-07-08 AT AT02764647T patent/ATE315022T1/de not_active IP Right Cessation
- 2002-07-08 ES ES02764647T patent/ES2254726T3/es not_active Expired - Lifetime
- 2002-07-08 RU RU2004104625/04A patent/RU2288913C2/ru not_active IP Right Cessation
- 2002-07-08 AU AU2002328855A patent/AU2002328855B2/en not_active Ceased
- 2002-07-08 CA CA002451392A patent/CA2451392A1/en not_active Abandoned
- 2002-07-11 PA PA20028550201A patent/PA8550201A1/es unknown
- 2002-07-11 PE PE2002000619A patent/PE20030257A1/es not_active Application Discontinuation
- 2002-07-15 UY UY27384A patent/UY27384A1/es not_active Application Discontinuation
- 2002-07-16 US US10/197,353 patent/US6900336B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
WO2003008377A1 (en) | 2003-01-30 |
PA8550201A1 (es) | 2003-02-14 |
US6900336B2 (en) | 2005-05-31 |
RU2004104625A (ru) | 2005-05-27 |
DE60208568D1 (de) | 2006-03-30 |
CA2451392A1 (en) | 2003-01-30 |
AU2002328855B2 (en) | 2005-11-24 |
ATE315022T1 (de) | 2006-02-15 |
BR0211201A (pt) | 2004-07-13 |
EP1409455B1 (en) | 2006-01-04 |
UY27384A1 (es) | 2003-01-31 |
DE60208568T2 (de) | 2006-10-05 |
EP1409455A1 (en) | 2004-04-21 |
RU2288913C2 (ru) | 2006-12-10 |
US20030120079A1 (en) | 2003-06-26 |
KR20040015364A (ko) | 2004-02-18 |
PL368046A1 (en) | 2005-03-21 |
JP2004521954A (ja) | 2004-07-22 |
ES2254726T3 (es) | 2006-06-16 |
MXPA04000456A (es) | 2004-03-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20030257A1 (es) | Analogos de 8-aza-11-desoxi-prostaglandina como agonistas del receptor ep4 | |
MXPA03011638A (es) | Nuevos derivados de 4-piperazinil indol con afinidad por el receptor 5-ht6. | |
MXPA03011244A (es) | Nuevos derivados de indol con afinidad por el receptor 5-ht6. | |
NO20025641D0 (no) | Substituerte 1-aminoalkyl-laktamer og deres anvendelse som muscarin-reseptor-antagonister | |
EA200600811A1 (ru) | НОВЫЕ ПРОИЗВОДНЫЕ ТЕТРАГИДРОСПИРО {ПИПЕРИДИН-2,7'-ПИРРОЛО [3,2-b]ПИРИДИНА} И НОВЫЕ ПРОИЗВОДНЫЕ ИНДОЛА, ПРИМЕНЕНИЕ ДЛЯ ЛЕЧЕНИЯ РАССТРОЙСТВ, СВЯЗАННЫХ С 5-HT-РЕЦЕПТОРОМ | |
MXPA04007414A (es) | Indoles sustituidos como agonistas alfa-1. | |
BR0317294A (pt) | Composto, formulação farmacêutica, uso de um composto, métodos de prevenção e/ou tratamento de condições associadas com a glicogênio sintase quinase-3 e de prevenção e/ou tratamento de doenças, e, uso dos intermediários | |
YU68102A (sh) | Derivati karboksilne kiseline kao ip antagonisti | |
NO20025640D0 (no) | Substituerte 1-aminoalkyl-laktamer og deres anvendelse som muscarin-reseptor-antagonister | |
MXPA05011710A (es) | Derivados de pirimidina con actividad de crf. | |
HK1070054A1 (en) | Arylsulfonyl derivatives with5-ht6 receptor affinity | |
AR035153A1 (es) | Derivados de carboxamidas y cetonas de dihidrobenzodioxina | |
MXPA05007341A (es) | Derivados de 2-piperidona como agonistas de prostaglandina. | |
YU53100A (sh) | Derivati 2-ariletil-(piperidin-4-ilmetil)amina kao antagonisti muskarinskih receptora | |
EA200300071A1 (ru) | Терапевтический препарат для лечения невроза страха (тревоги) или депрессии и производные пиперазина | |
HK1074842A1 (en) | Arylalkyl indoles having serotonin receptor affinity useful as therapeutic agents, process for their preparation and pharmaceutical compositions containing them | |
MXPA04005426A (es) | Derivados de pirazol de anillos fuisionados. | |
MXPA04005076A (es) | Derivados de 4-piperidinil alquilamina como antagonistas del receptor muscarinico. | |
MXPA04005313A (es) | Derivados de aminotetralin como antagonistas del receptor muscarinico. | |
HUP0002929A2 (hu) | Tachikinin receptor antagonista hatású 2-acilamino-propán-aminok és az ezeket tartalmazó gyógyszerkészítmények | |
PL1660484T3 (pl) | Metyloindole i metylopirolopirydyny jako agoniści receptora adrenergicznego α-1 | |
NZ543068A (en) | Substituted 4-(alkyl-amide)-piperidine derivatives, processes for their preparation, and pharmaceutical compositions containing them | |
SE0301371D0 (sv) | New Compounds | |
ECSP034870A (es) | Nuevos derivados de indol con afinidad por el receptor 5-ht6 | |
MX2008000781A (es) | Derivados de triazol substituidos y su uso como antagonistas del receptor neuroquinina 3. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FD | Application declared void or lapsed |